Page last updated: 2024-12-06
pipoxolan
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
pipoxolan: synonyms BR-18 & rowapraxin refer to HCl; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 28932 |
| CHEMBL ID | 2110645 |
| CHEBI ID | 135483 |
| SCHEMBL ID | 669035 |
| MeSH ID | M0040125 |
Synonyms (35)
| Synonym |
|---|
| rowapraxin (tn) |
| CHEBI:135483 |
| pipoxolan |
| 23744-24-3 |
| D07369 |
| pipoxolan (inn) |
| 5,5-diphenyl-2-(2-piperidin-1-ylethyl)-1,3-dioxolan-4-one |
| unii-493gzj5t6i |
| pipossolano [dcit] |
| pipoxolanum [inn-latin] |
| 493gzj5t6i , |
| pipoxolanum |
| 1,3-dioxolan-4-one, 5,5-diphenyl-2-(2-(1-piperidinyl)ethyl)- |
| pipossolano |
| pipoxolan [inn:ban] |
| 5,5-diphenyl-2-[2-(1-piperidyl)ethyl]-1,3-dioxolan-4-one hydrochloride |
| 5,5-diphenyl-2-(2-piperidinoethyl)-1,3-dioxolan-4-one |
| 5,5-diphenyl-2-(2'-piperidinoethyl)-1,3-dioxolan-4-one |
| (+/-)-5,5-diphenyl-2-(2-piperidinoethyl)-1,3-dioxolan-4-one |
| 27769-60-4 |
| 1,3-dioxolan-4-one, 5,5-diphenyl-2-(2-piperidinoethyl)- |
| pipoxolan [who-dd] |
| pipoxolan [mart.] |
| 5,5-diphenyl-2-(2-(1-piperidinyl)ethyl)-1,3-dioxolan-4-one |
| pipoxolan [inn] |
| SCHEMBL669035 |
| CHEMBL2110645 |
| 5,5-diphenyl-2-[2-(1-piperidinyl)ethyl]-1,3-dioxolan-4-one # |
| DXSUDONPFZKWOO-UHFFFAOYSA-N |
| BCP20276 |
| br 18 pound>>br18 pound>>br-18 |
| Q27259212 |
| A848113 |
| 5,5-diphenyl-2-[2-(piperidin-1-yl)ethyl]-1,3-dioxolan-4-one |
| DTXSID20865113 |
Research Excerpts
Effects
Pipoxolan (PIPO) has anti-spasmodic effects, and it is used clinically to relieve smooth muscle spasms. Pipoxolan has been reported to have antitumor activity.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Pipoxolan has also been shown to have anticancer activity." | ( Pipoxolan Exhibits Antitumor Activity Toward Oral Squamous Cell Carcinoma Through Reactive Oxygen Species-mediated Apoptosis. Chou, PY; Lee, MM; Lin, SY; Sheu, MJ, 2017) | 2.62 |
| "Pipoxolan (PIPO) has anti-spasmodic effects, and it is used clinically to relieve smooth muscle spasms. " | ( Pipoxolan ameliorates cerebral ischemia via inhibition of neuronal apoptosis and intimal hyperplasia through attenuation of VSMC migration and modulation of matrix metalloproteinase-2/9 and Ras/MEK/ERK signaling pathways. Chen, YF; Siao, LR; Tsai, HY; Wood, WG; Wu, KJ, 2013) | 3.28 |
| "Pipoxolan has been reported to have antitumor activity. " | ( Pipoxolan inhibits CL1-5 lung cancer cells migration and invasion through inhibition of MMP-9 and MMP-2. Chen, YY; Hsu, S; Lee, MM; Liu, PY; Sheu, MJ, 2015) | 3.3 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| diarylmethane | Any compound containing two aryl groups connected by a single C atom. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 39.67
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (39.67) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (14.29%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (85.71%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||